PMID- 14609222
OWN - NLM
STAT- MEDLINE
DCOM- 20040408
LR  - 20051116
IS  - 1528-2511 (Print)
IS  - 1528-2511 (Linking)
VI  - 252
DP  - 2003
TI  - Dendritic cells: controllers of the immune system and a new promise for 
      immunotherapy.
PG  - 226-35; discussion 235-8, 257-67
AB  - Dendritic cells (DCs) can be utilized either as vectors or as targets for 
      therapy. Patients with metastatic melanoma received CD34-DC vaccine that contains 
      Langerhans' cells and interstitial DCs. DCs were pulsed with MART1, tyrosinase, 
      MAGE3, gp100 and Flu-MP peptides, and KLH. DCs induced an immune response to 
      control antigens in 16/18 patients. An enhanced immune response to 1 or more 
      melanoma antigens (MelAgs) was seen in these 16 patients. The two patients 
      failing to respond experienced rapid tumour progression. Six out of seven 
      patients with immunity to two or fewer MelAgs had progressive disease 10 weeks 
      after study entry, in contrast to tumour progression in only 1/10 patients with 
      immunity to > two MelAgs. Since tumour immunotherapy targets autologous antigens 
      we can learn from systemic autoimmunity such as systemic lupus erythematosus 
      (SLE). As opposed to normal monocytes, SLE monocytes induce proliferation of 
      allogeneic CD4+ T cells. SLE sera induce monocyte differentiation towards DCs in 
      an IFNalpha-dependent mechanism. Spiking autologous serum with IFNalpha 
      reproduces DC differentiation. 50% of SLE patients have high serum levels of 
      IFNalpha, which could explain T/B lymphopenia. Yet, plasmacytoid DCs, a major 
      IFNalpha source, are 80% decreased. pDCs and IFNalpha may play a role in SLE 
      pathogenesis and therapy.
FAU - Banchereau, Jacques
AU  - Banchereau J
AD  - Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, TX 75204, USA.
FAU - Fay, Joseph
AU  - Fay J
FAU - Pascual, Virginia
AU  - Pascual V
FAU - Palucka, A Karolina
AU  - Palucka AK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Novartis Found Symp
JT  - Novartis Foundation symposium
JID - 9807767
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immune Tolerance
MH  - Immunotherapy/*methods
MH  - Models, Immunological
MH  - Neoplasms/immunology/therapy
RF  - 9
EDAT- 2003/11/12 05:00
MHDA- 2004/04/09 05:00
CRDT- 2003/11/12 05:00
PHST- 2003/11/12 05:00 [pubmed]
PHST- 2004/04/09 05:00 [medline]
PHST- 2003/11/12 05:00 [entrez]
PST - ppublish
SO  - Novartis Found Symp. 2003;252:226-35; discussion 235-8, 257-67.